Adaptimmune (NASDAQ:ADAP): Q2 GAAP EPS of -$0.04 beats by $0.20. Revenue of $0.5M (+212.5% Y/Y) misses by $0.43M. Shares +1.15% PM. Press Release
seekingalpha · 2天前
Adaptimmune Reports Q2 Financial Results and Business Update
\- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -\- Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - \- Granted access to
GlobeNewswire · 2天前
Adaptimmune Therapeutics shares are trading higher after the company late Thursday reported it was granted access to priority medicines regulatory support by EMA for ADP-A2M4 for treatment of Synovial Sarcoma. UPDATE: Shares have since reversed.
Benzinga · 07/24 14:01
Adaptimmune Therapeutics shares are trading higher after the company reported it was granted access to priority medicines regulatory support by EMA for ADP-A2M4 for treatment of Synovial Sarcoma.
Benzinga · 07/23 20:12
Adaptimmune's ADP-A2M4 nabs accelerated review in EU for soft tissue cancer
Seeking Alpha - Article · 07/23 20:10
Adaptimmune Therapeutics reports Was Granted Access To PRIority MEdicines Regulatory Support By EMA For ADP-A2M4 For Treatment Of Synovial Sarcoma
Benzinga · 07/23 20:00
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative
GlobeNewswire · 07/23 20:00
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. marke